2628
E. Nuti et al. / European Journal of Medicinal Chemistry 46 (2011) 2617e2629
A.L. Harris, J. Verweij, Phase I and pharmacological study of the oral matrix
metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced
[29] U. Neumann, H. Kubota, K. Frei, V. Ganu, D. Leppert, Characterization of
McaeLyseProeLeueGlyeLeueDpaeAlaeArgeNH2, fluorogenic substrate
a
solid cancer, Clin. Cancer Res. 7 (2001) 1912e1922.
with increased specificity constants for collagenases and tumor necrosis factor
converting enzyme, Anal. Biochem. 328 (2004) 166e173.
[30] V. Dhanaraj, M.G. Williams, Q.-Z. Ye, F. Molina, L.L. Johnson, D.F. Ortwine,
A. Pavlovsky, J.R. Rubin, R.W. Skeean, A.D. White, C. Humblet, D.J. Hupe,
T.L. Blundell, X-ray structure of gelatinase A catalytic domain complexed with
a hydroxamate inhibitor, Croat. Chem. Acta 72 (1999) 575e591.
[11] P.A. Konstantinopoulos, M.V. Karamouzis, A.G. Papatsoris, A.G. Papavassiliou,
Matrix metalloproteinase inhibitors as anticancer agents, Int. J. Biochem. Cell.
Biol. 40 (2008) 1156e1168.
[12] C.M. Overall, O. Kleifeld, Tumour microenvironment e opinion: validating
matrix metalloproteinases as drug targets and anti-targets for cancer therapy,
Nat. Rev. Cancer 6 (2006) 227e239.
[31] D. Pei, Leukolysin/MMP25/MT6-MMP:
a novel matrix metalloproteinase
[13] D.P. Becker, T.E. Barta, L.J. Bedell, T.L. Boehm, B.R. Bond, J. Carroll, C.P. Carron,
G.A. Decrescenzo, A.M. Easton, J.N. Freskos, C.L. Funckes-Shippy, M. Heron,
S. Hockerman, C.P. Howard, J.R. Kiefer, M.H. Li, K.J. Mathis, J.J. McDonald,
P.P. Mehta, G.E. Munie, T. Sunyer, C.A. Swearingen, C.I. Villamil, D. Welsch,
specifically expressed in the leukocyte lineage, Cell Res. 9 (1999) 291e303.
[32] Q. Sun, C.R. Weber, A. Sohail, M.M. Bernardo, M. Toth, H. Zhao, J.R. Turner,
R. Fridman, MMP25 (MT6-MMP) is highly expressed in human colon cancer,
promotes tumor growth, and exhibits unique biochemical properties, J. Biol.
Chem. 282 (2007) 21998e22010.
J.M. Williams, Y. Yu, J. Yao, Orally active MMP-1 sparing
a-tetrahydropyranyl
and -piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with
efficacy in cancer, arthritis, and cardiovascular disease, J. Med. Chem. 53
(2010) 6653e6680.
a
[33] (a) G. Velasco, S. Cal, A. Merlos-Suárez, A.A. Ferrando, S. Alvarez, A. Nakano,
J. Arribas, C. López-Otín, Human MT6-matrix metalloproteinase: identifica-
tion, progelatinase A activation, and expression in brain tumors, Cancer Res.
60 (2000) 877e882;
[14] C. López-Otín, L.H. Palavalli, Y. Samuels, Protective roles of matrix metal-
loproteinases: from mouse models to human cancer, Cell Cycle 8 (2009)
3657e3662.
[15] (a) D.T. Puerta, J. Mongan, B.L. Tran, J.A. McCammon, S.M. Cohen, Potent,
selective pyrone-based inhibitors of stromelysin-1, J. Am. Chem. Soc. 127
(2005) 14148e14149;
(b) R.K. Nuttall, C.J. Pennington, J. Taplin, A. Wheal, V.W. Yong, P.A. Forsyth,
D.R. Edwards, Elevated membrane-type matrix metalloproteinases in gliomas
revealed by profiling proteases and inhibitors in human cancer cells, Mol.
Cancer Res. 1 (2003) 333e345.
[34] A. Sohail, Q. Sun, H. Zhao, M.M. Bernardo, J.A. Cho, R. Fridman, A unique set of
membrane-anchored matrix metalloproteinases: properties and expression in
cancer, Cancer Metastasis Rev. 27 (2008) 289e302.
[35] (a) A. Krüger, M.J. Arlt, M. Gerg, C. Kopitz, M.M. Bernardo, M. Chang,
S. Mobashery, R. Fridman, Antimetastatic activity of a novel mechanism-based
gelatinase inhibitor, Cancer Res. 65 (2005) 3523e3526;
(b) D.T. Puerta, M.O. Griffin, J.A. Lewis, D. Romero-Perez, R. Garcia,
F.J. Villarreal, S.M. Cohen, Heterocyclic zinc-binding groups for use in next-
generation matrix metalloproteinase inhibitors: potency, toxicity, and reac-
tivity, J. Biol. Inorg. Chem. 11 (2006) 131e138.
[16] Regarding the debate on the use of hydroxamates as ZBG for metalloenzymes
see: (a) E. Nuti, L. Panelli, F. Casalini, S.I. Avramova, E. Orlandini, S. Santamaria,
S. Nencetti, T. Tuccinardi, A. Martinelli, G. Cercignani, N. D’Amelio, A. Maiocchi,
F. Uggeri, A. Rossello, Design, synthesis, biological evaluation and NMR studies
(b) R.D. Bonfil, A. Sabbota, S. Nabha, M.M. Bernardo, Z. Dong, H. Meng,
H. Yamamoto, S.R. Chinni, I.T. Lim, M. Chang, L.C. Filetti, S. Mobashery,
M.L. Cher, R. Fridman, Inhibition of human prostate cancer growth, osteolysis
and angiogenesis in a bone metastasis model by a novel mechanism-based
selective gelatinase inhibitor, Int. J. Cancer 118 (2006) 2721e2726;
(c) A. Hoffman, B. Qadri, J. Frant, Y. Katz, S.R. Bhusare, E. Breuer, R. Hadar,
R. Reich, Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-
of
a new series of arylsulfones as selective and potent matrix metal-
loproteinase-12 inhibitors, J. Med. Chem. 52 (2009) 6347e6361;
(b) M. Flipo, J. Charton, A. Hocine, S. Dassonneville, B. Deprez, R. Deprez-
Poulain, Hydroxamates: relationships between structure and plasma stability,
J. Med. Chem. 52 (2009) 6790e6802.
aminocyclohexylcarbamoylphosphonic acid,
a novel orally active anti-
[17] (a) Y. Tamura, F. Watanabe, T. Nakatani, K. Yasui, M. Fuji, T. Komurasaki,
H. Tsuzuki, R. Maekawa, T. Yoshioka, K. Kawada, K. Sugita, M. Ohtani, Highly
selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-
2): N-sulfonylamino acid derivatives, J. Med. Chem. 41 (1998) 640e649;
(b) R. Kiyama, Y. Tamura, F. Watanabe, H. Tsuzuki, M. Ohtani, M. Yodo,
Homology modeling of gelatinase catalytic domains and docking simulations
of novel sulfonamide inhibitors, J. Med. Chem. 42 (1999) 1723e1738.
[18] (a) G.E. Terp, G. Cruciani, I.T. Christensen, F.S. Jorgensen, Structural differences of
matrix metalloproteinases with potential implications for inhibitor selectivity
examined by the GRID/CPCA approach, J. Med. Chem. 45 (2002) 2675e2684;
(b) L. Aureli, M. Gioia, I. Cerbara, S. Monaco, G.F. Fasciglione, S. Marini, P. Ascenzi,
A. Topai, M. Coletta, Structural bases for substrate and inhibitor recognition by
matrix metalloproteinases, Curr. Med. Chem. 15 (2008) 2192e2222.
[19] A. Agrawal, D. Romero-Perez, J.A. Jacobsen, F.J. Villarreal, S.M. Cohen, Zinc-
binding groups modulate selective inhibition of MMPs, Chem. Med. Chem. 3
(2008) 812e820.
metastatic matrix metalloproteinase-2 selective inhibitor e synthesis and
pharmacodynamic and pharmacokinetic analysis, J. Med. Chem. 51 (2008)
1406e1414;
(d) M. Lee, G. Celenza, B. Boggess, J. Blase, Q. Shi, M. Toth, M.M. Bernardo,
W.R. Wolter, M.A. Suckow, D. Hesek, B.C. Noll, R. Fridman, S. Mobashery,
M. Chang, A potent gelatinase inhibitor with anti-tumor-invasive activity and
its metabolic disposition, Chem. Biol. Drug Des. 73 (2009) 189e202.
[36] P. Gabelloni, E. Da Pozzo, S. Bendinelli, B. Costa, E. Nuti, F. Casalini,
E. Orlandini, F. Da Settimo, A. Rossello, C. Martini, Inhibition of metal-
loproteinases derived from tumours: new insights in the treatment of human
glioblastoma, Neuroscience 168 (2010) 514e522.
[37] L.J. MacPherson, E.K. Bayburt, M.P. Capparelli, B.J. Carroll, R. Goldstein,
M.R. Justice, L. Zhu, S. Hu, R.A. Melton, L. Fryer, R.L. Goldberg, J.R. Doughty,
S. Spirito, V. Blancuzzi, D. Wilson, E.M. O’Byrne, V. Ganu, D.T. Parker, Discovery
of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor
that blocks cartilage degradation in rabbits, J. Med. Chem. 40 (1997)
2525e2532.
[20] A.Rossello,E.Nuti,P.Carelli,E.Orlandini, M.Macchia,S.Nencetti,M. Zandomeneghi,
F. Balzano, G. Uccello Barretta, A. Albini, R. Benelli, G. Cercignani, G. Murphy,
A. Balsamo, N-i-propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as
potent and selective inhibitors of MMP-2 and MT1-MMP, Bioorg. Med. Chem. Lett.
15 (2005) 1321e1326.
[38] C.G. Knight, F. Willenbrock, G. Murphy, A novel coumarin-labelled peptide for
sensitive continuous assays of the matrix metalloproteinases, FEBS Lett. 296
(1992) 263e266.
[39] SoftMax Pro 4.7.1 by Molecular Devices.
[21] S. Hanessian, D.B. MacKay, N. Moitessier, Design and synthesis of matrix
metalloproteinase inhibitors guided by molecular modeling. Picking the S(1)
pocket using conformationally constrained inhibitors, J. Med. Chem. 44 (2001)
3074e3082.
[22] B.R. Neustadt, Facile preparation of N-(sulfonyl)carbamates, Tetrahedron Lett.
35 (1994) 379e380.
[23] K. Sonogashira, Y. Tohda, N. Hagihara, Convenient synthesis of acetylenes:
catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes,
and bromopyridines, Tetrahedron Lett. 50 (1975) 4467e4470.
[40] GraFit version 4 by Erithecus Software.
[41] Glide, Version 5.5. Schrödinger, LLC, New York, NY, 2009.
[42] Maestro, Version 9.0.211. Schrodinger, L.L.C., New York, NY, 2009.
[43] E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt,
E.C. Meng, T.E. Ferrin, UCSF chimera e a visualization system for exploratory
research and analysis, J. Comput. Chem. 25 (2004) 1605e1612.
[44] A.W. Schuttelkopf, D.M. van Aalten, PRODRG: a tool for high-throughput
crystallography of proteineligand complexes, Acta Crystallogr. Sect. D Biol.
Crystallogr. 60 (2004) 1355e1363.
[24] E. Shirakawa, T. Sato, Y. Imazaki, T. Kimura, T. Hayashi, Cobalt-catalyzed cross-
coupling of alkynyl Grignard reagents with alkenyl triflates, Chem. Commun.
43 (2007) 4513e4515.
[45] J.W. Storer, D.J. Giesen, C.J. Cramer, D.G. Truhlar, Class IV charge models:
a new semiempirical approach in quantum chemistry, J. Comput-Aided Mol.
Des 9 (1995) 87e110.
[25] E. Nuti, E. Orlandini, S. Nencetti, A. Rossello, A. Innocenti, A. Scozzafava,
C.T. Supuran, Carbonic anhydrase and matrix metalloproteinase inhibitors.
Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and
II with sulfonylated hydroxamates, Bioorg. Med. Chem. 15 (2007) 2298e2311.
[26] D.P. Becker, C.I. Villamil, T.E. Barta, L.J. Bedell, T.L. Boehm, G.A. Decrescenzo,
J.N. Freskos, D.P. Getman, S. Hockerman, R. Heintz, S.C. Howard, M.H. Li,
J.J. McDonald, C.P. Carron, C.L. Funckes-Shippy, P.P. Mehta, G.E. Munie,
C.A. Swearingen, Synthesis and structure-activity relationships of beta- and
alpha-piperidine sulfone hydroxamic acid matrix metalloproteinase inhibitors
with oral antitumor efficacy, J. Med. Chem. 48 (2005) 6713e6730.
[27] S.L. Zheng, S. Reid, N. Lin, B. Wang, Microwave-assisted synthesis of ethyny-
larylboronates for the construction of boronic acid-based fluorescent sensors
for carbohydrates, Tetrahedron Lett. 47 (2006) 2331e2335.
[46] J.D. Thompson, C.J. Cramer, D.G. Truhlar, Parameterization of charge model 3
for AM1, PM3, BLYP, and B3LYP, J. Comput. Chem. 24 (2003) 1291e1304.
[47] W.L. Jorgensen, D.S. Maxwell, J. TiradoeRives, Development and testing of the
OPLS all-atom force field on conformational energetics and properties of
organic liquids, J. Am. Chem. Soc. 118 (1996) 11225e11236.
[48] W.L.B.O.S.S. Jorgensen, Version 4.6. Yale University, New Haven, CT, 2004.
ꢀ
[49] M. Udier-Blagovic, P. Morales De Tirado, S.A. Pearlman, W.L. Jorgensen,
Accuracy of free energies of hydration using CM1 and CM3 atomic charges,
J. Comput. Chem. 25 (2004) 1322e1332.
[50] R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz,
M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, D.E. Shaw, P. Francis,
P.S. Shenkin, Glide: a new approach for rapid, accurate docking and scoring. 1.
Method and assessment of docking accuracy, J. Med. Chem. 47 (2004)
1739e1749.
[28] B.C. Shook, D. Chakravarty, P.F. Jackson, Microwave-assisted Sonogashira-type
cross couplings of various heterocyclic methylthioethers, Tetrahedron Lett. 50
(2009) 1013e1015.
[51] R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood,
T.A. Halgren, P.C. Sanschagrin, D.T. Mainz, Extra precision glide: docking and